Wayne A. Schellhammer

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.